|
|
| Drug Name: | Isosorbide Dinitrate |
| Manufacturer: | Sandoz Inc. |
| Other Info: | Rev. 04-2004M7185Manufactured bySandoz Inc.Broomfield, CO 80020 |
| Clinical Trials: | |
Isosorbide dinitrate tablets are indicated for the prevention of angina pectoris due to coronary artery disease.
The onset of action of immediate-release oral isosorbide dinitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode.Allergic reactions to organic nitrates are extremely rare, but they do occur.
Isosorbide dinitrate tablets are contraindicated in patients who are allergic to isosorbide dinitrate or any other component of the product.Amplification of the vasodilatory effects of isosorbide dinitrate by sildenafil can result in severe hypotension.
The time course and dose dependence of this interaction have not been studied.
Appropriate supportive care has not been studied, but it seems reasonable to treat this as a nitrate overdose, with elevation of the extremities and with central volume expansion.The benefits of immediate release oral isosorbide dinitrate in patients with acute myocardial infarction or congestive heart failure have not been established.
If one elects to use isosorbide dinitrate in these conditions, careful clinical or hemodynamic monitoring must be used to avoid the hazards of hypotension and tachycardia.
Because the effects of oral isosorbide dinitrate are so difficult to terminate rapidly, this formulation is not recommended in these settings.
NIH - Clinical Trials